Polycystic Ovary Syndrome as a Determinant of Female Infertility: A Prevalence-Based Analytical Study
Keywords:
Polycystic ovary syndrome, infertilityAbstract
Polycystic ovarian syndrome (PCOS) is a prominent endocrine situation in women of a reproductive age. It is characterized by high testosterone levels, menstrual abnormalities, and/or tiny cysts on one or both ovaries. The condition may be anatomical (polycystic ovaries) or primarily biochemical (hyperandrogenemia). Hyperandrogenism, a clinical characteristic of PCOS, may impede follicular growth, result in ovarian microcysts, cause anovulation, and induce monthly irregularities. Before attempting to conceive, most women with polycystic ovarian syndrome PCOS are unaware of their condition. OBJECTIVE: Aim to determine the prevalence of polycystic ovary syndrome (PCOS) in infertile women visiting AL-DIWANAH maternity and children teaching hospital's Infertility Treatment and the common features of those with and without PCOS. METHODOLOGY: Seven-month cross-sectional research from September 2018 to March 2019 reviewed the records of all 600 women who frequented AL-DIWANAH maternity and children teaching hospital. RESULTS: The findings indicated that the predominant causes of infertility in women include polycystic ovary syndrome (PCOS), which exhibited a greater prevalence among women aged 20 to 44 years. CONCLUSION: PCOS-related infertility accounts for around one-fourth of infertility cases and is mostly linked to primary infertility during the age period of 20 to 44 years.
References
-Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685-97 .
-Cela E, Robertson C, Rush K .women with acne: hormone profiles and clinical findings. J Pakistan Association of Dermatologists 2010; 20: 194-98.
-Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011. p. 1393.
-Lin LH, Baracat MC, Gustavo AR, et al. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynaecol Obstet. 2013;120:115–118.
-Joan C. Lo, Seth L. Feigenbaum, Jingrong Yang, Alice R. Pressman, Joe V. Selby and Alan S. Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome. J Clinical Endocrinology & Metabolism (JCEM) 2006; 91: 1357.
-Zacur HA. Epidemiology, clinical manifestations and pathophysiology of polycystic ovary syndrome. Adv. Stud Med. 2003; 3: S733-S739
-Review Article Polycystic ovary syndrome: definition, etiology, diagnosis and treatment,https://doi.org/10.1038/nrendo.2018.24,
-Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002;147:717–725.
-Polycystic ovary syndrome fact sheet - Updated April 2014, jeanhailes.org.au/health-a-z/pcos.
-Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30:19–26.
-Shannon M, Wang Y. Polycystic ovary syndrome: A common but often unrecognized condition. J Midwifery Womens Health. 2012;57:221–230.
-Urbanek M. The genetics of polycystic ovary syndrome. Natl Clin Pract Endocrinol Metab. 2007;3:103–111.
-www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg33
-Marshall K. Polycystic ovary syndrome clinical consideration. Altern Med Rev. 2001; 6:272-292.
-Patel SM, Nestler JE. Fertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2006;35(1):137-155.
-Ehrmann DA ,Barnes RB, Rosefield RL ,Cavaghan MK , Imperial J . Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome .Diabetes Care.1999; 22:141_6
-Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyper-androgenic syndrome. An Androgen Excess Society guideline. J Clin Edocrinol Metab. 2006;91:4237–4245.
-Norman RJ. Wu R, Stankiewicz MT. Polycystic ovary syndrome.MJA. 2004;180(3):132-137
-Hanaa Rahman Eleawi*, Enas Talib Abdul-Karim**, Anam Rasheed AL- Salihi***,2015-Study of Occurrence of Polycystic Ovarian Syndrome Among Infertile Women.
-Balen A, Mickelmore K. What is polysystic ovary syndrome. Human Reproduction. 2002; 17(9):2219-2227.
-Hunter MH, Sterrett JJ. Polycystic Ovary Syndrome: it`s Not Just Infertility. American Academy of Family Physicians. 2000; 62(5).
-Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs. 2006;66(7):903-912.2-
-Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L.Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858-2864.
-Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril. 2006;85(4):1002-1009
-Svendsen PF, Madsbad S, Nilas L. The insulin-resistant phenotype of polycystic ovary syndrome. Fertil Steril. 2010;94(3):1052-1058
-Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002;13(6):251-257.
-Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1360-1365.
-Tian L, Shen H, Lu Q, Norman RJ, Wang J. Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab. 2007;92(4):1430–1433.
-Jungheim ES, Lanzendorf SE, Odem RR, Moley KH, Chang AS, Ratts VS. Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. Fertil Steril. 2009;92(1):256–261.
-Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndromeFertil Steril. 2003;80(2):255-258.
-Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010;94(5):1565-1574.
-Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810-1812.
-Barth JH, Cherry CA, Wojnarowskaf, Dawber RPR. Cyproterome acetate for sever hirsutism: result of a double-blind dose-ranging study. Clin Endocrinal 1991; 35: 5-10
-Edwar Z.Khosho, Ahlam Abdul-Hadi & Hutham W.A. Al-Serrai , REVALENCE OF POLYCYSTIC OVARIES IN GYNAECOLOGICAL POPULATION, Department of Obstetrics & Gynecology, College of Medicine, University of Basrah, Iraq, 2010.
-Sharma ST, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinal Metab. 2006;20(2): 245-260.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Al-Qadisiyah Journal for Biomedical and Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
